Bremelanotide
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoactive Sexual Desire Disorder
Conditions
Hypoactive Sexual Desire Disorder
Trial Timeline
Dec 1, 2014 → Jun 30, 2017
NCT ID
NCT02333071About Bremelanotide
Bremelanotide is a phase 3 stage product being developed by Palatin Technologies for Hypoactive Sexual Desire Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02333071. Target conditions include Hypoactive Sexual Desire Disorder.
What happened to similar drugs?
0 of 1 similar drugs in Hypoactive Sexual Desire Disorder were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02333071 | Phase 3 | Completed |
| NCT01382719 | Phase 2 | Completed |
Competing Products
4 competing products in Hypoactive Sexual Desire Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + 0.5 mgTestosterone + 10 mg Buspirone | Brain Biotech | Phase 2 | 25 |
| Placebo + Testosterone + Buspirone hydrochloride | Brain Biotech | Phase 2 | 25 |
| Placebo + Sildenafil + Testosterone | Brain Biotech | Phase 2 | 25 |
| Bremelanotide + Placebo | Palatin Technologies | Phase 3 | 30 |